Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(34), p. TPS3103-TPS3103, 2016
DOI: 10.1200/jco.2016.34.15_suppl.tps3103
Links
Tools
Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).
Journal article published in 2016 by
Ann-Lii Cheng,
Yoon-Koo Kang,
Andrew X. Zhu,
Richard D. Kim,
Masatoshi Kudo,
Michael Morse,
Ghassan K. Abou-Alfa,
Bruno Sangro,
Johanna Bendell,
Shannon R. Morris,
Feng Xiao,
Joyce Antal,
Jillian Boice,
Stephen Lam Chan 
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 